doxorubicin

(redirected from Caelyx)
Also found in: Dictionary, Medical, Wikipedia.
Related to Caelyx: Doxil, Myocet
  • noun

Words related to doxorubicin

an antibiotic used as an anticancer drug

References in periodicals archive ?
EP572,049B1 and EP445,131B1, based on the sales of Caelyx.
Therefore, CAELYX should not be used interchangeably with other formulations of doxorubicin hydrochloride.
Doxil and Caelyx are PEGylated liposomes encapsulating the drug doxorubicin.
The results of this trial show that the combination of CAELYX and carboplatin are similar to standard therapy and may potentially offer low neurotoxicity rates.
Continuous supply of medicinal Caelyx, according to the client~s needs and according to detailed specifications in the tender documents.
CAELYX is the first anthracycline to show a significant level of efficacy in relapsed ovarian cancer.
This Phase III study compares monotherapy liposomal doxorubicin, a Johnson & Johnson product(x) known as CAELYX(R) in Europe, and DOXIL(R) (doxorubicin HCI liposome injection) in the US, to a combination of YONDELIS and CAELYX (DOXIL) in ovarian cancer patients who have relapsed after receiving standard first-line chemotherapy.
Nevertheless, the comparison between periods is affected by the sale of raw materials to partner Janssen Pharmaceuticals for 3 million euro in 1H11, and by the fact that the supply of Caelyx had not yet been interrupted in 1H11.
It will also compare Caelyx with another, low-dose combination of anticancer drugs.
Arimidex, Aromasin, Alimta, Avastin, Bay 43-9006, Bexxar, BMS-247550, CAELYX, Campath, Camptosar, CCI-779, Edotecarin, Erbitux, Eloxatin, Faslodex, Gemzar, Gleevec, Herceptin, IMC-BEC2, Iressa, Lapatinib, MelVax, PTK787, PI-88, Revlimid, SARASAR, SU11248, Tarceva, Temodal, Thalomid,Tirazone, Velcade, Xeloda, Xcytrin
4-1BBL, 506U78, Actimmune, Ad-IFNg, AlloMune, AMD-3100, Aplidin, ASIbcl, Atragen, Avastin, BCX1777, B-E8, Beta LT, Bexxar, Caelyx, Calsed, Campath, Clofarabine, CMC-544, CpG-7909, Depocyte, Edodekin Alpha, Elsamitrucin, FAVID, Fludara, FR-901228, Ganite, GEMZAR, GENASENSE, GRN163, GTI-2040, GTOP-99, hA20, HMR1275, HSPPC-96, Hu1D10, hum291, HuMax, IDEC-114, IDEC-152, IDIOVAX, Intron A, INX-3280, ISF-154, KiroMAb, LY317615, Lymphocide, Lymphorad131, MDX-060, MGV, Midostaurin, MT103, NIPENT, NOVATRONE, Oncolym, OncoTCS, Ontak, Orathecin Rubitecan, Parlodel, PEGIntron, Porleukin, Pretarget Lymphoma, PRO64553, Product R, Prothecan, Remitogen, Rituxan, SGN-30, SGN-35, T-900607, TH9402, Thalidomid, Trap, TRISENOX, UCN-01, VAXID, VB2-011, VEGF Trap, VELCADE, Zevalin
As previously announced, SEQUUS has entered into a distribution agreement with Schering-Plough under which Schering-Plough has exclusive rights to distribute, market and sell CAELYX worldwide, except for the United States, Japan and certain other markets.
Several other products also contributed to the operational sales growth including REMICADE (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; vaccines, proteins and antibodies from Crucell that prevent and/or treat infectious diseases; PREZISTA (darunavir), a treatment for HIV; CAELYX (pegylated liposomal doxorubicin hydrochloride), a treatment for certain types of cancer; and VELCADE (bortezomib), a treatment for multiple myeloma.
In addition, Schering-Plough will fund a portion of the clinical development program for CAELYX, conduct clinical trials for a solid tumor indication, apply for regulatory approval in the Schering-Plough territories for all new indications, and assist with pharmacoeconomic studies.
Several other products also contributed to the operational sales growth including REMICADE (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA (darunavir), a treatment for HIV; CAELYX (pegylated liposomal doxorubicin hydrochloride), a treatment for certain types of cancer; LEVAQUIN (levofloxacin), a treatment for bacterial infections; and international sales of RISPERDAL CONSTA (risperidone), a long-acting injectable for the management of Bipolar I Disorder and schizophrenia.